Analysts Downgrade Incyte Target to $107 Amid Market Adjustments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 20 2026
0mins
Source: Benzinga
- Incyte Price Target Cut: Wells Fargo downgraded Incyte's price target from $116 to $107 and changed its rating from Overweight to Equal-Weight, reflecting a cautious market sentiment as shares closed at $106.21 on Friday.
- Uber Target Adjustment: Keybanc reduced Uber's price target from $110 to $105 while maintaining an Overweight rating, indicating analysts' confidence in Uber's future growth, with shares closing at $84.85 on Friday.
- Philip Morris Downgrade: Jefferies cut Philip Morris's price target from $220 to $180 and downgraded its rating from Buy to Hold, reflecting concerns about the company's future performance as shares closed at $173.62 on Friday.
- Prologis Price Target Increase: Truist Securities raised Prologis's price target from $131 to $142 while maintaining a Buy rating, indicating analysts' optimism about its future growth, with shares closing at $133.21 on Friday.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INCY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INCY
Wall Street analysts forecast INCY stock price to fall
19 Analyst Rating
9 Buy
9 Hold
1 Sell
Moderate Buy
Current: 107.530
Low
73.00
Averages
100.31
High
125.00
Current: 107.530
Low
73.00
Averages
100.31
High
125.00
About INCY
Incyte Corporation is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of therapeutics. The Company operates in three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity (IAI). Its hematology franchise includes four approved products, JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) and NIKTIMVO (axatilimab-csfr), as well as multiple clinical development programs. Its oncology franchise includes two approved products, PEMAZYRE (pemigatinib) and ZYNYZ (retifanlimab-dlwr), as well as several clinical development programs. Its Inflammation and Autoimmunity franchise is comprised of one approved product, OPZELURA (ruxolitinib) cream, with several clinical programs in development. The Company manages business activities on a consolidated basis through the development and commercialization of oncology and dermatology products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Opzelura Receives Positive CHMP Opinion for Moderate Atopic Dermatitis Treatment
- Breakthrough Treatment Option: If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free topical JAK treatment in the EU, addressing a significant gap for moderate atopic dermatitis patients, potentially benefiting 230 million individuals globally.
- Clinical Trial Success: The Phase 3 TRuE-AD4 study demonstrated that ruxolitinib cream met both co-primary endpoints at Week 8, with 84.3% of patients maintaining EASI75 at Week 24, indicating its long-term efficacy in managing symptoms.
- Quality of Life Improvement: Patients treated with ruxolitinib cream showed a significant reduction in Dermatology Life Quality Index (DLQI) scores from 19.3 at baseline to 4.3, highlighting the treatment's effectiveness in alleviating symptoms and enhancing overall quality of life.
- Good Safety Profile: During the 24-week treatment period, ruxolitinib cream reported no serious infections or major adverse events, with common side effects including upper respiratory tract infections (10.6%), indicating its favorable tolerability and safety profile.
See More
Star Therapeutics Announces VGA039 Study Data Presentation at ISTH 2026
- Clinical Data Presentation: Star Therapeutics will present complete safety and efficacy data for VGA039 at the ISTH 2026 Congress, which is expected to enhance its market recognition in the treatment of bleeding disorders.
- Acquisition Agreement: Incyte has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25 billion, which will add VGA039 to Incyte's hematology portfolio and strengthen its competitive position.
- Significant Treatment Potential: VGA039 is poised to be the first subcutaneous prophylactic therapy for all types of von Willebrand disease with a once-monthly dosing regimen, potentially improving patient quality of life and reducing treatment frequency.
- FDA Accelerated Designations: VGA039 has received multiple designations from the FDA, including Fast Track and Breakthrough Therapy, indicating its significant potential and promising market outlook in the treatment landscape.
See More
U.S. Stocks Close Lower on Friday, Chipmakers Weigh on Market
- Market Decline: The S&P 500 and Nasdaq 100 fell by 0.05% and 1.09% respectively on Friday, reaching two-week lows, indicating market sensitivity to the weak performance of chipmakers, which could undermine investor confidence.
- Chipmaker Sell-off: The significant drop in Samsung Electronics and SK Hynix shares led to a more than 5% decline in South Korea's Kospi Index, triggering a global downturn in semiconductor stocks and exacerbating market uncertainty.
- Oil Price Impact: WTI crude oil prices fell over 3% to a four-month low on Friday, which helps lower inflation expectations and supports the stock market, but also reflects potential slowdowns in global economic growth.
- Consumer Sentiment Revision: The University of Michigan's consumer sentiment index was revised upward by 0.6 to 49.5, although still below the expected 50.0, indicating a cautious consumer outlook that may affect future spending.
See More
Incyte Breaks Out of Seven-Month Range
- Price Movement Analysis: Biopharmaceutical company Incyte has been in a sideways trend since November, but it is now breaking out of a seven-month range, indicating a strong bullish signal that could push the stock price above $125.
- Buy Recommendation: Analysts recommend buying Incyte shares at the current price level, believing that this breakout will yield higher returns, reflecting market optimism about the company's future performance.
- Technical Chart Interpretation: Two identical charts annotate the current market setup in different ways, both conveying a bullish message, suggesting that investors should pay attention to this potential upward trend.
- Market Sentiment Shift: As the stock price breaks out, market sentiment may shift positively, attracting more investors to Incyte, further driving its stock price up and enhancing market confidence.
See More
US Stock Market Under Pressure as Chip Stocks Plummet
- Market Weakness: The S&P 500 and Nasdaq 100 indices fell by 0.07% and 0.75%, respectively, reaching two-week lows, indicating market sensitivity to the weak performance of chipmakers, which may lead to declining investor confidence.
- Chip Stock Plunge: The significant sell-off of Samsung Electronics and SK Hynix caused the South Korean Kospi index to drop over 5%, triggering a global decline in chip stocks and exacerbating market uncertainty.
- Oil Price Decline Impact: WTI crude oil prices fell by more than 3%, easing inflation expectations and supporting stocks; however, the recovery of crude exports to 75% of pre-war levels may influence future market dynamics.
- Consumer Sentiment Revision: The University of Michigan's consumer sentiment index was revised upward to 49.5, although still below the expected 50.0, reflecting cautious consumer attitudes towards the economic outlook, which could affect retail and consumer-related stocks.
See More
EU Drug Regulator Endorses Six New Medicines for Approval
- New Drug Approvals: The European Medicines Agency endorsed six new medicines and 11 label expansions this week, which is expected to significantly benefit drugmakers including Eli Lilly (LLY), Incyte (INCY), and CSL Limited (CSLLY).
- Eli Lilly's Progress: Eli Lilly announced that its cancer drug Jaypirca received a positive opinion from the EMA's Committee for Medicinal Products for Human Use for chronic lymphocytic leukemia treatment, with final approval anticipated in the next one to two months, further solidifying its market position in blood cancer therapies.
- Incyte Label Expansion: Incyte's JAK inhibitor Opzelura (ruxolitinib) cream received a positive opinion from the EMA, and if finalized, it will serve as a second-line treatment for moderate atopic dermatitis, expanding its market application.
- CSL Vaccine Approval: CSL Limited's subsidiary Seqirus Netherlands received EU backing for its Aujemflu vaccine to prevent influenza in individuals aged 50 and above, enhancing its competitive edge in the vaccine market.
See More
Opzelura Receives Positive CHMP Opinion for Moderate Atopic Dermatitis Treatment
- Breakthrough Treatment Option: If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free topical JAK treatment in the EU, addressing a significant gap for moderate atopic dermatitis patients, potentially benefiting 230 million individuals globally.
- Clinical Trial Success: The Phase 3 TRuE-AD4 study demonstrated that ruxolitinib cream met both co-primary endpoints at Week 8, with 84.3% of patients maintaining EASI75 at Week 24, indicating its long-term efficacy in managing symptoms.
- Quality of Life Improvement: Patients treated with ruxolitinib cream showed a significant reduction in Dermatology Life Quality Index (DLQI) scores from 19.3 at baseline to 4.3, highlighting the treatment's effectiveness in alleviating symptoms and enhancing overall quality of life.
- Good Safety Profile: During the 24-week treatment period, ruxolitinib cream reported no serious infections or major adverse events, with common side effects including upper respiratory tract infections (10.6%), indicating its favorable tolerability and safety profile.
See More
Star Therapeutics Announces VGA039 Study Data Presentation at ISTH 2026
- Clinical Data Presentation: Star Therapeutics will present complete safety and efficacy data for VGA039 at the ISTH 2026 Congress, which is expected to enhance its market recognition in the treatment of bleeding disorders.
- Acquisition Agreement: Incyte has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25 billion, which will add VGA039 to Incyte's hematology portfolio and strengthen its competitive position.
- Significant Treatment Potential: VGA039 is poised to be the first subcutaneous prophylactic therapy for all types of von Willebrand disease with a once-monthly dosing regimen, potentially improving patient quality of life and reducing treatment frequency.
- FDA Accelerated Designations: VGA039 has received multiple designations from the FDA, including Fast Track and Breakthrough Therapy, indicating its significant potential and promising market outlook in the treatment landscape.
See More
U.S. Stocks Close Lower on Friday, Chipmakers Weigh on Market
- Market Decline: The S&P 500 and Nasdaq 100 fell by 0.05% and 1.09% respectively on Friday, reaching two-week lows, indicating market sensitivity to the weak performance of chipmakers, which could undermine investor confidence.
- Chipmaker Sell-off: The significant drop in Samsung Electronics and SK Hynix shares led to a more than 5% decline in South Korea's Kospi Index, triggering a global downturn in semiconductor stocks and exacerbating market uncertainty.
- Oil Price Impact: WTI crude oil prices fell over 3% to a four-month low on Friday, which helps lower inflation expectations and supports the stock market, but also reflects potential slowdowns in global economic growth.
- Consumer Sentiment Revision: The University of Michigan's consumer sentiment index was revised upward by 0.6 to 49.5, although still below the expected 50.0, indicating a cautious consumer outlook that may affect future spending.
See More
Incyte Breaks Out of Seven-Month Range
- Price Movement Analysis: Biopharmaceutical company Incyte has been in a sideways trend since November, but it is now breaking out of a seven-month range, indicating a strong bullish signal that could push the stock price above $125.
- Buy Recommendation: Analysts recommend buying Incyte shares at the current price level, believing that this breakout will yield higher returns, reflecting market optimism about the company's future performance.
- Technical Chart Interpretation: Two identical charts annotate the current market setup in different ways, both conveying a bullish message, suggesting that investors should pay attention to this potential upward trend.
- Market Sentiment Shift: As the stock price breaks out, market sentiment may shift positively, attracting more investors to Incyte, further driving its stock price up and enhancing market confidence.
See More
US Stock Market Under Pressure as Chip Stocks Plummet
- Market Weakness: The S&P 500 and Nasdaq 100 indices fell by 0.07% and 0.75%, respectively, reaching two-week lows, indicating market sensitivity to the weak performance of chipmakers, which may lead to declining investor confidence.
- Chip Stock Plunge: The significant sell-off of Samsung Electronics and SK Hynix caused the South Korean Kospi index to drop over 5%, triggering a global decline in chip stocks and exacerbating market uncertainty.
- Oil Price Decline Impact: WTI crude oil prices fell by more than 3%, easing inflation expectations and supporting stocks; however, the recovery of crude exports to 75% of pre-war levels may influence future market dynamics.
- Consumer Sentiment Revision: The University of Michigan's consumer sentiment index was revised upward to 49.5, although still below the expected 50.0, reflecting cautious consumer attitudes towards the economic outlook, which could affect retail and consumer-related stocks.
See More
EU Drug Regulator Endorses Six New Medicines for Approval
- New Drug Approvals: The European Medicines Agency endorsed six new medicines and 11 label expansions this week, which is expected to significantly benefit drugmakers including Eli Lilly (LLY), Incyte (INCY), and CSL Limited (CSLLY).
- Eli Lilly's Progress: Eli Lilly announced that its cancer drug Jaypirca received a positive opinion from the EMA's Committee for Medicinal Products for Human Use for chronic lymphocytic leukemia treatment, with final approval anticipated in the next one to two months, further solidifying its market position in blood cancer therapies.
- Incyte Label Expansion: Incyte's JAK inhibitor Opzelura (ruxolitinib) cream received a positive opinion from the EMA, and if finalized, it will serve as a second-line treatment for moderate atopic dermatitis, expanding its market application.
- CSL Vaccine Approval: CSL Limited's subsidiary Seqirus Netherlands received EU backing for its Aujemflu vaccine to prevent influenza in individuals aged 50 and above, enhancing its competitive edge in the vaccine market.
See More
